Pfizer CEO Highlights Multiple GLP-1 Weight-Loss Candidates in Pipeline
Pfizer CEO Albert Bourla highlighted the firm’s GLP-1 receptor agonist weight-loss pipeline, confirming multiple candidates in early clinical and preclinical development targeting obesity management. He underscored metabolic therapies as a growth driver alongside the cardiovascular portfolio.
1. CEO Comments on GLP-1 Pipeline
Pfizer CEO Albert Bourla outlined the company’s GLP-1 receptor agonist weight-loss drug pipeline, stating that several candidates are advancing through early clinical trials and preclinical testing. He emphasized that metabolic therapies targeting obesity will complement Pfizer’s existing cardiovascular and rare disease portfolios as a strategic growth area.
Related News
NVDA
Nvidia Raises Dividend to $0.25, Launches $80B Buyback after $91B Forecast
NVDA•
ENHA
Enhanced Trial Shifts to Five-Year Monitoring After 91% Athlete Testosterone Use
ENHA•
TQQQ
ProShares 3x Nasdaq-100 ETF Gathers $31.3B, Hits 38.6% YTD Gain
TQQQ•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
SVM
Silvercorp Secures 30-Year License Extension, Pays $60M for Tulkubash/Kyzyltash JV
SVM•
Sources
F